Citation Impact
Citing Papers
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Elastase-Induced Parenchymal Disruption and Airway Hyper Responsiveness in Mouse Precision Cut Lung Slices: Toward an Ex vivo COPD Model
2017
COPD Guidelines: A Review of the 2018 GOLD Report
2018 Standout
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
2013
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
2016
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
2016
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
2014
Idiopathic pulmonary fibrosis
2017 Standout
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
2016
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
2017 Standout
2018
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program
2017
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
2019
Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial
2020
Nrf2 attenuates inflammatory response in COPD /emphysema: Crosstalk with Wnt3a/β‐catenin and AMPK pathways
2018 Standout
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Works of Hungta Chen being referenced
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study
2013
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
2013
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study
2012
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
2015
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
2015